Kane Biotech's Q3 2024: A Pivotal Moment in Wound Care
Thursday, Nov 28, 2024 4:24 pm ET
3min read Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced its third quarter 2024 financial results, marking a significant milestone in the company's growth trajectory. Focusing on its revyveTM Antimicrobial Wound Gel, Kane Biotech has witnessed remarkable strides in revenue and profitability, solidifying its position in the wound care market.
The company's total revenue for the three months ended September 30, 2024, was $1,282,698, a staggering 47-fold increase compared to the same period in 2023. Gross profit for the quarter surged to $558,754, up 24-fold year-over-year. The company's product sales, driven by its revyveTM Antimicrobial Wound Gel, contributed significantly to this growth, with $594,705 in first commercial sales recorded during the quarter.
Kane Biotech's gross profit and net loss in Q3 2024 were primarily driven by a significant increase in product sales and the commencement of product services revenue. The company's first commercial sales of revyveTM Antimicrobial Wound Gel, totaling $594,705, were a major contributor to gross profit. Additionally, the initiation of animal health manufacturing and quality control services, which generated $685,021 in product services revenue, also played a crucial role.
Kane Biotech's operating expenses for the third quarter of 2024 were $1,170,064, an increase of 18% compared to $994,801 for the three months ended September 30, 2023. This increase was primarily due to higher employee compensation, consulting, travel, and investor relations expenses recorded in the current period.
Looking ahead, Kane Biotech's acquisition of FB Dermatology and its expansion into new markets, such as Qatar and the UAE, may continue to drive revenue growth. Additionally, the company's research and development collaboration with a multinational corporate partner for its DispersinB® Wound Gel could lead to further innovation and market penetration. Overall, Kane Biotech's strong third quarter results and strategic initiatives suggest a positive outlook for the coming quarters.
The company's total revenue for the three months ended September 30, 2024, was $1,282,698, a staggering 47-fold increase compared to the same period in 2023. Gross profit for the quarter surged to $558,754, up 24-fold year-over-year. The company's product sales, driven by its revyveTM Antimicrobial Wound Gel, contributed significantly to this growth, with $594,705 in first commercial sales recorded during the quarter.
Kane Biotech's gross profit and net loss in Q3 2024 were primarily driven by a significant increase in product sales and the commencement of product services revenue. The company's first commercial sales of revyveTM Antimicrobial Wound Gel, totaling $594,705, were a major contributor to gross profit. Additionally, the initiation of animal health manufacturing and quality control services, which generated $685,021 in product services revenue, also played a crucial role.
Kane Biotech's operating expenses for the third quarter of 2024 were $1,170,064, an increase of 18% compared to $994,801 for the three months ended September 30, 2023. This increase was primarily due to higher employee compensation, consulting, travel, and investor relations expenses recorded in the current period.
Looking ahead, Kane Biotech's acquisition of FB Dermatology and its expansion into new markets, such as Qatar and the UAE, may continue to drive revenue growth. Additionally, the company's research and development collaboration with a multinational corporate partner for its DispersinB® Wound Gel could lead to further innovation and market penetration. Overall, Kane Biotech's strong third quarter results and strategic initiatives suggest a positive outlook for the coming quarters.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.